RxDoctor Payments DataLook up a doctor →

Diego Mastronardi, MD

Family Medicine · Bowling Green, KYNPI 1104822626

Payments from drug & device makers

$195,633in general payments, 2019–2025

Across 567 payments — averaging $345.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$114K
  • AstraZeneca$74K
  • AbbVie$1K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$980
  • Amgen$883
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$8,23298%
  • Education$1922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$195,633 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$287,459
Medicare patients
391
Services billed
23,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide149$139,311
Synjardy XrEmpagliflozin/Metformin Hcl61$72,640
TrulicityDulaglutide49$69,059
EliquisApixaban53$50,946
JardianceEmpagliflozin58$46,860
MounjaroTirzepatide35$40,446
XareltoRivaroxaban27$35,717
FarxigaDapagliflozin Propanediol18$26,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$24,620
OxycontinOxycodone Hcl13$23,306
MyrbetriqMirabegron13$15,222
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$13,823
SynthroidLevothyroxine Sodium114$6,905
Mirabegron ErMirabegron11$6,767
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$6,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSynjardy Xr, Jardiance, Stiolto Respimat, Glyxambi$1,118$139,546149 claims
Novo NordiskOzempic$980$139,311149 claims
Lilly USA, LLCTrulicity, Mounjaro$265$109,50484 claims
PfizerEliquis$654$50,94653 claims
Johnson & JohnsonXarelto$59$35,71727 claims
GSKTrelegy Ellipta, Arnuity Ellipta$337$27,63530 claims
AstraZenecaFarxiga$74,361$26,29018 claims
Astellas Pharma US IncMyrbetriq$89$15,22213 claims
AbbVieSynthroid$1,226$6,905114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →